Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G., Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leal, Ticiana A., Riess, Jonathan W., Jensen, Erin, Zhao, Bin, Pietanza, M. Catherine, Brahmer, Julie R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089/
https://www.ncbi.nlm.nih.gov/pubmed/33872070
http://dx.doi.org/10.1200/JCO.21.00174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089/
https://www.ncbi.nlm.nih.gov/pubmed/33872070
http://dx.doi.org/10.1200/JCO.21.00174

Ejemplares similares